Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

Abramson Cancer Center at Penn Medicine

Status: Invitation-only

Conditions: Cardiotoxicity; Breast Cancer; Coronary Microvascular Dysfunction; Lung Cancer (NSCLC)

Study type: Observational

Funder types: Other

Identifiers

NCT06332131

UPCC07623

Details and patient eligibility

About

This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy. The investigators will use echocardiograms, blood draws, and PET stress tests to understand how ICI therapy affects the heart and circulatory system.

Enrollment: 25 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥18 years of age
• Either diagnosis of breast cancer with plan for treatment according to the Keynote 522 regimen or non-small-cell lung cancer planned for neoadjuvant treatment that includes pembrolizumab
• Able to provide written informed consent

Exclusion criteria

• Pregnant or breast-feeding:
• Prior treatment with ICI therapy.
• Vulnerable patients, including pregnant women and prisoners
• Absolute Contraindication to rest/vasodilator stress PET/CT